Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast

被引:3
|
作者
Laube, Beth L. [1 ]
Carson, Kathryn A. [2 ]
Sharpless, Gail [1 ]
Paulin, Laura M. [3 ]
Hansel, Nadia N. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pediat, 200 North Wolfe St,Room 3015, Baltimore, MD 21287 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
chronic obstructive pulmonary disease (COPD) and chronic bronchitis; former tobacco smokers; mucociliary clearance; roflumilast; scintigraphy; TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; COUGH CLEARANCE; DEPOSITION; INFECTIONS; INHIBITION; VALIDATION; TRANSPORT; SMOKING; AIRWAYS;
D O I
10.1089/jamp.2018.1459
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Little is known of the repeatability and reliability of mucociliary clearance (MCC) in former tobacco smokers who have both chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB). Less is known of the effect of roflumilast, a selective inhibitor of PDE4, on MCC in these patients. Methods: Former tobacco smokers with COPD and CB were treated for 4 weeks with either roflumilast, or placebo, in a randomized, crossover trial. The following were measured on two baseline and two posttreatment visits: MCC values through 90 minutes, following inhalation of (99m)technetium sulfur colloid and gamma camera imaging; outer:inner (O:I) deposition ratio; forced expiratory volume in 1 second (FEV1); and symptom scores. Comparisons included: MCC measures through 30 minutes (MCC30), 60 minutes (MCC60), and 90 minutes (MCC90) on the two baseline visits (n = 9) and mean change [(roflumilast - baseline)-(placebo - baseline)] for MCC30, MCC60, MCC90, and FEV1 (n = 8). Associations between MCC measurements, FEV1 and O:I ratio with symptom scores were also examined. Results: Pearson correlation tests indicated good repeatability for baseline measures of MCC30, MCC60, and MCC90 and intraclass correlation coefficients indicated good reliability. Only FEV1 (percent predicted) improved significantly following roflumilast treatment. There were no statistically significant correlations between MCC measures and symptom scores. Lower FEV1 values were significantly associated with increased shortness of breath (dyspnea), and lower O:I ratios (more inner region deposition) were significantly associated with increased cough and sputum. Conclusions: Measurements of MCC30, MCC60, and MCC90 are repeatable and reliable in former tobacco smokers with both COPD and CB. One month of treatment with roflumilast did not improve MCC in this limited study. Airway narrowing in the larger, central airways of these subjects could lead to decreased FEV1, increased inner region deposition of the radiolabeled particles, and the associated increase in symptoms of dyspnea, cough, and sputum.
引用
收藏
页码:189 / 199
页数:11
相关论文
共 50 条
  • [21] Roflumilast for the treatment of chronic obstructive pulmonary disease
    Antoniu, SA
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (05) : 412 - 417
  • [22] Roflumilast for eosinophilic chronic obstructive pulmonary disease?
    Han, MeiLan K.
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 802 - 803
  • [23] Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease
    Jeffery, PK
    CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PATHOGENESIS TO TREATMENT, 2001, 234 : 149 - 168
  • [24] Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
    Liu, Dong-yang
    Wang, Zhi-guo
    Gao, Yuan
    Zhang, Hui-min
    Zhang, Yu-xiang
    Wang, Xiao-jun
    Peng, Dan
    MEDICINE, 2018, 97 (07)
  • [25] Effect of roflumilast on cytokines levels in patients with Chronic Obstructive Pulmonary Disease
    Ostrovskyy, Mykola
    Savelikhina, Iryna
    Ostrovska, Kseniia
    Varunkiv, Oleksandr
    Kulynych-Miskiv, Mariana
    Korzh, Galyna
    Shvets, Kostiantyn
    Korzh, Nadiia
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [26] Acquired Cftr Dysfunction Is Associated With Bronchiectasis In Smokers And Former Smokers With Chronic Obstructive Pulmonary Disease
    Teerapuncharoen, K.
    Wells, J. M.
    Raju, S. V.
    Rasmussen, L.
    Nath, H.
    Diaz, A. A.
    Estepar, R. San Jose
    Washko, G.
    Bhatt, S. P.
    Solomon, G. M.
    Dransfield, M. T.
    Rowe, S. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [27] Systemic Galectin-3 in Smokers with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis: The Impact of Exacerbations
    Sundqvist, Martina
    Andelid, Kristina
    Ekberg-Jansson, Ann
    Bylund, Johan
    Karlsson-Bengtsson, Anna
    Linden, Anders
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 367 - 377
  • [28] What is the role of roflumilast in chronic obstructive pulmonary disease?
    Lau, Chris
    Mehta, Atul C.
    Hatipoglu, Umur
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2017, 84 (01) : 13 - 15
  • [29] Roflumilast: A Novel Treatment for Chronic Obstructive Pulmonary Disease
    Reid, Debra J.
    Pham, Nga T.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (04) : 521 - 529
  • [30] The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
    Cazzola, Mario
    Calzetta, Luigino
    Rogliani, Paola
    Matera, Maria Gabriella
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (07) : 733 - 744